Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’…
Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not…
Clarivate Epidemiology’s coverage of methicillin-resistant staphylococcus aureus (MRSA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the…
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs…
The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…
Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…
Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…
Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…